Stockwinners Market Radar for March 12, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:10 EDT Green Dot exec buys $299K in common stock - In a regulatory filing, Green Dot disclosed that its Chief Revenue Officer Christian Ruppel bought 33K shares of common stock on March 11th in a total transaction size of $299K. Shares of Green Dot were up 3% afterhours at $9.00 following the disclosure.

20:37 EDT Barnes & Noble Education affirms FY24 adjusted EBITDA view of about $40M

20:23 EDT Cathie Wood's ARK Investment bought 278K shares of Nu Holdings today

20:05 EDT Logan Ridge Finance to delay final Q4 report due to tax-related item - Logan Ridge Finance "announced that it will delay the investor conference call previously scheduled for 10:00 am ET on Thursday, March 14, 2024. Additional time is required to complete the year-end financial statements due to a tax-related item that is not expected to impact the company's net asset value or net income. The company will issue a separate press release when a rescheduled date and time has been determined. The company expects to report its results coincident with, or prior to, the filing of its Annual Report on Form 10-K for the year ended December 31, 2023."

19:55 EDT Logan Ridge Fiance to delay Q4 - - Logan Ridge Finance "announced that it will delay the investor conference call previously scheduled for 10:00 am ET on Thursday, March 14, 2024. Additional time is required to complete the year-end financial statements due to a tax-related item that is not expected to impact the Company's net asset value or net income. The Company will issue a separate press release when a rescheduled date and time has been determined. The Company expects to report its results coincident with, or prior to, the filing of its Annual Report on Form 10-K for the year ended December 31, 2023."

19:50 EDT Hempacco Co Inc trading halted, news pending

18:58 EDT Poseida Therapeutics' treatment of multiple myeloma gets FDA orphan designation - According to a post on the FDA's website, Poseida Therapeutics' treatment of multiple myeloma received orphan designation. Reference Link

18:17 EDT Microsoft CCO Althoff sells 10,000 common shares - In a regulatory filing, Microsoft chief commercial officer Judson Althoff disclosed the sale of 10,000 common shares of the company on March 11 at a price of $403.649 per share.

17:38 EDT Bell Textron awarded $455M Navy contract - Bell Textron was awarded a $455M firm-fixed-price, undefinitized contract for the production and delivery of 12 AH-1Z helicopters for the government of Nigeria, as well as provides associated engineering, program management and logistics support, and non-recurring engineering for obsolescence. Work is expected to be completed in July 2028. Foreign Military Sales customer funds in the amount of $82.35M will be obligated at time of award, none of which will expire at the end of the current fiscal year. This contract was not competitively procured pursuant to 10 U.S. Code 3204. Naval Air Systems Command Patuxent River is the contracting activity.

17:30 EDT InvenTrust Properties raises dividend 5% to 22.6c - InvenTrust Properties announced that its Board of Directors declared a Q1 cash distribution of 22.6c per share of common stock, which represents a 5% year-over-year increase. When annualized, this is equal to a rate of 90.5c per share. This distribution will be paid on or about April 15 to stockholders of record as of March 31.

17:28 EDT InvenTrust Properties raises dividend 5% to 22.5c - InvenTrust Properties announced that its Board of Directors declared a Q1 cash distribution of 22.6c per share of common stock, which represents a 5% year-over-year increase. When annualized, this is equal to a rate of 90.5c per share. This distribution will be paid on or about April 15 to stockholders of record as of March 31.

17:19 EDT Copa Holdings reports February capacity up 17%, traffic up 17.5% - The company states: "For February 2024, Copa Holdings' capacity increased by 17.0%, while system-wide passenger traffic also increased by 17.5%, compared to 2023. As a result, the system load factor for the month was 86.3%, 0.3 percentage points higher than in February 2023."

16:58 EDT Avid Bioservices to delay 10-Q filing, must restate Q3 financials - The company stated: "As previously reported in a Current Report on Form 8-K, filed by Avid Bioservices, Inc. with the Securities and Exchange Commission on March 6, 2024, on February 29, 2024, the Company received an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026. The Acceleration Notice stipulated, among other things, that (i) the Company did not remove the restrictive legend on the 2026 Notes by March 17, 2022 as required under the indenture governing the 2026 Notes , (ii) due to such failure, additional interest has accrued thereafter at a rate of 0.50% per annum, (iii) such Additional Interest had not been paid by the Company as of the date of the Acceleration Notice, which constitutes an event of default under the 2026 Notes Indenture, and (iv) such holder is the beneficial owner of at least 25% in aggregate principal amount of the outstanding 2026 Notes and therefore has the right to accelerate all of the 2026 Notes. As a result of the Event of Default, such holder declared 100% of the principal of, and accrued and unpaid interest on, the 2026 Notes to be due and payable immediately. The Company did not receive any notices and was not otherwise made aware of the Event of Default prior to receipt of the Acceleration Notice, and did not have an opportunity to cure the Event of Default at the time of receipt of the Acceleration Notice. In connection with the Event of Default, the Company undertook an evaluation as to whether certain of the financial statements included in the Company's Quarterly Reports on Form 10-Q for the quarterly fiscal periods ended October 31, 2022, January 31, 2023, July 31, 2023 and October 31, 2023, and in its Annual Report on Form 10-K for the fiscal year ended April 30, 2023 (the "FY 2023 10-K" and collectively with the foregoing Form 10-Qs, the "Relevant Reports" and the periods covered by the Relevant Reports, the "Relevant Periods") should no longer be relied upon as a result of: the classification of the 2026 Notes as long-term liabilities on the applicable balance sheets within the Relevant Reports following the Event of Default; and the failure to reflect the Additional Interest in such financial statements. On March 11, 2024, the Audit Committee of the Company's Board of Directors determined, based on management's recommendation and after consultation with Ernst & Young LLP, the Company's independent registered public accounting firm, that as a result of the classification of the 2026 Notes as long-term liabilities, the consolidated financial statements included in the Relevant Reports should no longer be relied upon. In light of the foregoing, the Company must restate the impacted financial statements and file such restated financial statements with the SEC before it can file its Quarterly Report on Form 10-Q for the quarterly fiscal period ended January 31, 2024."

16:45 EDT Aterian backs prior view of 'adjusted EBITDA profitable' in 2H24 - The Company is reaffirming its prior guidance of expecting to be Adjusted EBITDA profitable in the second half of 2024.

16:42 EDT Rackspace Technology announces refinancing transactions - Rackspace Technology announced that it has closed a private debt exchange with certain of its creditors representing more than 72% of the company's first lien term loans and more than 64% of its first lien notes, as well as 100% of its revolving credit facility, or RCF, commitments. Through the private exchange, Rackspace has eliminated more than $375M of net debt and has received $275M of new money that will come to the balance sheet as additional liquidity to advance key strategic initiatives. Additionally, the maturities on the RCF and other participating senior debt facilities were extended to May 2028. In connection with the transaction, the company plans to launch a public debt exchange offer to all its outstanding lenders and first lien noteholders. The public exchange offer will offer existing lenders and first lien noteholders new term loans or new first lien notes, as applicable, with an improved security position, tighter covenants, and other restrictions. Through full participation in the public exchange offer, the company has the opportunity to eliminate more than $600M in net debt, reducing net annual interest expense by approximately $13M. These transactions represent another significant step forward in the company's capital structure evolution. Following the closing of the public exchange offer and assuming full participation, Rackspace will have raised $575M of new capital over the past 12 months, reducing the company's net financial debt by over $900M during such period and lowering its net annual interest expense by approximately $40M. In addition, with the extension and amendment of the RCF, Rackspace will continue to have access to the full $375M available under the RCF, bringing total liquidity to over $700M. There will be no change in Rackspace's equity ownership as a result of the transaction, which significantly decreases the company's debt balance and reduces its interest expense.

16:40 EDT Voxeljet trading resumes

16:35 EDT General Motors names former Tesla exec Jens Peter Clausen to lead manufacturing - General Motors (GM) announced the retirement of its long-serving executive vice president of Global Manufacturing and Sustainability, Gerald Johnson. Replacing him as the new executive vice president is Jens Peter Clausen, whom GM calls "an industrial leader with vast expertise in global manufacturing, product engineering and scaling operations." GM also announced that Mike Abbott, executive vice president of Software and Services, will be stepping down due to health reasons. JP Clausen "brings a strong track record of manufacturing, innovation, and operational excellence" having "spearheaded the rapid scaling of electric vehicle propulsion systems at Tesla's Gigafactory 1 and played a crucial role in making EVs more accessible," according to GM. "He also led a financial turnaround at LEGO by simplifying the product and component portfolio, and at Google Data Centers, as vice president of Engineering, he drove groundbreaking technological innovation, product development, and process optimization," GM stated. Reference Link

16:31 EDT Tempur Sealy provides update on acquisition of Mattress Firm Group - Tempur Sealy International provided an update with respect to the Company's acquisition of Mattress Firm Group. On May 9 Tempur Sealy signed a definitive agreement to acquire Mattress Firm, the largest mattress specialty retailer in the U.S. The Company continues to work with the FTC to advance the transaction, and now expects that the FTC will complete its review by the end of the Q2. Consistent with previous expectations, the Company continues to expect the transaction to close in mid to late 2024. Tempur Sealy and Mattress Firm continue to make joint progress in planning for post-closing, including solidifying Mattress Firm's key supplier relationships ahead of the expected closing.

16:24 EDT inTEST acquires Alfamation S.p.A., terms not stated - inTEST Corporation "announced that it has acquired Alfamation S.p.A., a leading global provider of state-of-the-art test and measurement solutions for the automotive, life sciences and specialty consumer electronics markets. Terms of the acquisition are being filed separately with the Securities and Exchange Commission. Alfamation will become a part of the Electronic Test division within inTEST. Alfamation is well known in the automotive test and measurement industry for Flexmedia XM(R), its family of specialty test tools. This is a modular, robust and cost-effective solution for building flexible, scalable, functional testers for applications that include audio and video generators and analyzers, automotive ethernet and communication interfaces, and analog measurements."

16:22 EDT Voxeljet announces restatement, extension of loan financing with Anzu - Voxeljet and Anzu's industrial technology investment fund agreed to amend and restate the existing loan note which the company has issued to Anzu with a principal amount of USD 3,209,483.12 and a maturity date of January 3, 2028 and to agree on an additional new loan note. The New Loan Note has a principal amount of $5.5M which will be made available in two tranches of $2.75M each, the first tranche upon Anzu having received duly executed collateral documentation and the second tranche on July 15, 2024 (or such earlier date determined by either party). The New Loan Note has a maturity date of June 30, 2026, but may be due earlier for repayment if a fundamental change as defined in the New Loan Note occurs. The Existing Loan Note has been amended and restated to largely equal the terms and conditions of the New Loan Note.

16:21 EDT Voxeljet accelerates strategic realignment, plans to delist ADSs from Nasdaq - Voxeljet announced its plan to voluntarily delist its ADSs from The Nasdaq Stock Market LLC and to terminate the registration of its ADSs with the U.S. Securities and Exchange Commission. The Company is taking these steps in order to reduce expenses and thereby to further strengthen its financial position. The Company has concluded that the benefits associated with a NASDAQ listing do not justify the costs and demands on management's time necessary to comply with SEC requirements. Consequently, the Company intends to start the process to delist the Company's shares from NASDAQ. After the NASDAQ delisting becomes effective, the Company intends to promptly initiate the process for suspending its reporting obligations under the Securities Exchange Act of 1934, as amended

16:18 EDT PHX Minerals sees FY24 total production 9,100Mmcfe-10,000Mmcfe

16:11 EDT Crinetics reports topline results from paltusotine study - Crinetics announced topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome. The Phase 2 trial was a randomized, open-label, parallel group, multi-center study evaluating the safety, tolerability, pharmacokinetics, and efficacy of paltusotine in people living with carcinoid syndrome. A total of 36 participants were randomized to receive either 40 mg or 80 mg of paltusotine for eight weeks, with the ability to dose titrate based on tolerability or inadequate control of symptoms during the first four weeks of treatment. Six participants in the 40 mg group increased their dose to 80 mg, and three participants in the 80 mg group increased to 120 mg. Thirty patients completed the randomized treatment phase, with one patient from the 40 mg group and five patients from the 80 mg group discontinuing treatment. Twenty-six of the 30 participants who completed the randomized treatment phase enrolled in the long-term extension phase of the study. Rapid and sustained reductions in flushing episodes and bowel movement; 63% reduction in mean flushing frequency for patients with greater than1/day at baseline; 60% reduction in mean excess BM frequency in patients with greater than3/day at baseline; 61% reduction in mean flushing severity and 64% reduction in mean BM urgency; reductions in frequency and severity of symptoms were observed within two weeks of paltusotine treatment and sustained through eight weeks in both naive/untreated patients and those switching from prior somatostatin receptor ligand therapy; overall pharmacokinetic profile of paltusotine in patients with carcinoid syndrome was consistent with expectations from healthy volunteers. Paltusotine was generally well-tolerated with a safety profile consistent with prior clinical studies. There were no treatment related severe or serious adverse events. The most frequently reported AEs included diarrhea, abdominal pain, nausea and headache AE findings were similar across 40 mg and 80 mg dosing groups. Levels of biomarkers serotonin and 5HIAA provide additional evidence of paltusotine activity in carcinoid syndrome.

16:06 EDT Teledyne to acquire Valeport, terms not stated - Teledyne Technologies "announced that it has entered into an agreement to acquire Valeport Holdings Limited and its affiliates. Valeport, founded in 1969 and headquartered in Totnes, United Kingdom, designs and manufactures underwater sensors for environmental, energy, construction and defense applications. Terms of the transactions were not disclosed. Valeport provides complementary underwater sensors including sound velocity probes, current and flow meters, and conductivity, temperature and depth sensors. Valeport also provides multi-parameter profilers which can also measure turbidity or cloudiness, or include fluorometer sensors to detect chlorophyll levels."

16:05 EDT Purple Innovation enters settlement agreement with Tempur Sealy - Purple Innovation (PRPL) announced that it has entered into a settlement agreement with Tempur Sealy International (TPX). The parties have agreed to a post-acquisition framework for Purple's partnership with Mattress Firm, subject to FTC approval of TSI's acquisition of Mattress Firm, and amicably resolved their various intellectual property disputes. Purple is pleased to reaffirm its valid patent and trademark rights in and to its proprietary Hyper-Elastic Polymer gel material, the key component in Purple's GelFlex Grid. If the FTC does not object to Tempur Sealy's acquisition of Mattress Firm, Tempur Sealy agrees that Purple will retain its current relationship with Mattress Firm for a minimum of twelve months, versus the two-month commitment in place previously. According to Rob DeMartini, CEO of Purple Innovation: "Mattress Firm is an important and respected partner. We believe our Purple brand and products bring a high number of unique consumers into Mattress Firm stores. We appreciate working on an even playing field today and want to continue to work collaboratively with Mattress Firm. This agreement will give us time to explore expansion opportunities." Purple and Tempur Sealy have also agreed to amicably resolve all differences regarding their various intellectual property disputes. Although the specific terms of the deal are confidential, Purple retains all control and ownership over its brand, its patented mattress technology and its Hyper-Elastic Polymer and GelFlex Grid marks. That the parties were able to resolve their differences is a strong signal to the marketplace that Purple is an innovator in hybrid mattress technology and deter future threats to Purple's business. DeMartini adds: "The marketplace's interest in gel technology recognizes the strength of what makes Purple's unmatched sleep innovation disruptive and cutting edge, and the best way of delivering deep, uninterrupted sleep. We are pleased to focus on expanding Purple's business and bringing the many benefits of our GelFlex Grid to more customers."

16:01 EDT Voxeljet trading halted, news pending

14:11 EDT Aeterna Zentaris, Ceapro merger approved by securityholders at special meetings - Aeterna Zentaris (AEZS) and Ceapro (CRPOF) announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings held today. The transaction is subject to customary closing conditions, including Alberta court approval and applicable stock exchange approvals. Subject to obtaining all required approvals and satisfying all required conditions, the transaction is expected to close in the second quarter of 2024. Following closing, a new name for the combined company will be announced for shareholders of the combined company to consider and approve at the first annual meeting of the combined company. The combined company is expected to be listed on the Nasdaq and the TSX, subject to the receipt of all necessary approvals.

14:03 EDT Pure Storage, SGH lower after Wedbush discusses Meta's new AI clusters - Shares of Pure Storage (PSTG) and SGH (SGH) are both lower after Wedbush released a note discussing Meta's (META) new AI clusters and possible implications for vendors. In afternoon trading, shares of Pure Storage are down $3.48, or 6%, to $50.58, while those of SGH are down 24c, or 1%, to $22.77.

12:29 EDT Biden Administration releases freight truck infrastructure strategy - The Biden-Harris Administration released its "National Zero-Emission Freight Corridor Strategy." Developed by the Joint Office of Energy and Transportation and U.S. Department of Energy, in collaboration with the Department of Transportation and the Environmental Protection Agency, the strategy will guide the deployment of zero-emission medium- and heavy-duty vehicle charging and hydrogen fueling infrastructure from 2024 to 2040, the administration said in a statement. The strategy "is designed to meet growing market demands by targeting public investment to amplify private sector momentum, focus utility and regulatory energy planning, align industry activity, and improve air quality in local communities heavily impacted by diesel emissions." It added, "Battery electric and hydrogen fuel cell vehicle technology along with other zero-emission forms of freight transport have considerable potential to save Americans money on consumer goods thanks to reduced fueling and maintenance costs associated with transport, all while delivering significant health benefits for historically disadvantaged populations that suffer the worst impacts of pollution from freight emissions and helping achieve national climate goals." Reference Link

12:14 EDT Southport Acquisition Corp trading resumes

12:00 EDT Asana falls -11.3% - Asana is down -11.3%, or -$2.13 to $16.66.

12:00 EDT Southwest falls -14.0% - Southwest is down -14.0%, or -$4.74 to $29.05.

12:00 EDT Mountain Crest Acquisition Corp IV trading resumes

12:00 EDT Ranpak Holdings rises 43.7% - Ranpak Holdings is up 43.7%, or $1.91 to $6.28.

11:55 EDT Mountain Crest Acquisition Corp IV trading halted, volatility trading pause

11:09 EDT National Bank of Canada says not engaged in ABA sale process - National Bank of Canada said in a statement: "Following the publication of media articles this morning, and while it is not customary for National Bank to comment on market rumors, the Bank is currently not engaged in any process or negotiations for the sale of ABA Bank, nor has it hired any advisors. ABA is a success story, delivering strong growth and superior returns for National Bank...We continue to be pleased with its performance and strong track record, its talented management team, strong execution and prudent risk management. National Bank continues to support ABA's growth and participation in the establishment of a sound and resilient banking industry for Cambodia, underpinned by attractive economic prospects and strong fundamentals."

11:03 EDT Reformed Energy announces investment from Riot Platforms - Reformed Energy has secured a strategic investment from Riot Platforms. By processing solid and liquid waste streams in its closed plasma gasification system, Reformed Energy can effectively prevent over 99% of the methane emissions and pollution that occurs with traditional waste disposal methods while reducing the physical volume of waste by about 90%. This process yields a versatile synthesis gas that can be utilized downstream for sustainable power generation and synthetic fuel production. In short, the company's unique technology has the ability to clean up existing landfills and reduce incoming waste streams. The self-contained system does not require grid interconnection and generates carbon neutral power while actively reducing existing methane emissions. This investment provides Reformed Energy with the capital to begin the development of its pilot site, where municipal solid waste will serve as the primary waste stream for generating sustainable power for its initial operations. In addition to MSW, Reformed Energy plans to incorporate tires, wood waste, industrial sludges, among other waste streams into its waste-to-energy processes. Upon the successful completion of the pilot site development, the site will serve as a training and demonstration center for parties seeking to leverage Reformed Energy's technology. Subsequent sites will be considered for development once the pilot site achieves operational scale, commencing our growth journey towards producing synthetic fuels including sustainable aviation fuel and providing cheap power to potential power offtake customers, in a mass commercial scale format.

10:54 EDT Instructure sees organic CAGR 9%-11% from year-end 2023-2028 - In investor day presentation slides, Instructure says it sees "growth across multiple vectors powers $1B ARR exit velocity in 2028" and guides to an organic compound annual growth rate, or CAGR, of 9%-11% from year-end 2023-2028, $1B total GAAP revenue by 2028 and adjusted EBITDA margin that expands to "mid 40s" by 2028. Reference Link

10:47 EDT FDA says 'not clear' magnitude, durability of RBC-TI outweighs Geron drug risks - In background information prepared by the Food and Drug Administration for the panel members of the Oncology Drugs Advisory Committee Meeting being convened on March 14 to discuss whether the efficacy of Geron's imetelstat demonstrated on Study 63935937MDS3001 in adult patients with lower-risk myelodysplastic syndromes, or MDS, outweigh the risks of treatment, the FDA staff stated: "FDA acknowledges that the results of Study MDS3001-Phase 3 met the statistical goals for the primary endpoint of 8-week RBC-TI and key secondary endpoint of 24-week RBC-TI, but the following issues in the study design and efficacy results were identified: It is not clear that the magnitude and durability of RBC-TI outweighs the risks of treatment with imetelstat for patients with lower-risk MDS; The HI-E, CR, PR, and OS results are not supportive of a disease-modifying treatment effect; The patient-reported outcomes are not supportive of a treatment effect." Reference Link

10:25 EDT DHC Acquisition Corp trading resumes

10:15 EDT DHC Acquisition Corp trading halted, volatility trading pause

10:06 EDT Table Trac says Taos Mountain Casino selects CasinoTrac CMS - Table Trac announced a new agreement to replace a competitor's system with the CasinoTrac casino management system, at Taos Mountain Casino, in Taos, New Mexico. Taos Mountain casino will be the company's first installation in New Mexico. Taos Mountain will install PlayerLINQ-CasinoTrac's 6.2" touchscreen player tracking interface, CTLoyalty and slot accounting solutions, along with DataTrac, the company's proprietary business intelligence and analytics platform.

10:03 EDT Aptorum Group Ltd trading resumes

10:00 EDT Southwest falls -12.1% - Southwest is down -12.1%, or -$4.09 to $29.69.

10:00 EDT Oracle rises 11.3% - Oracle is up 11.3%, or $12.87 to $127.00.

10:00 EDT Ranpak Holdings rises 46.2% - Ranpak Holdings is up 46.2%, or $2.02 to $6.39.

09:55 EDT SolarMax Technology Inc trading resumes

09:48 EDT Tecogen announces order for 12 Cogeneration units - Tecogen announced an order for 12 Tecopower Cogeneration units from an existing project developer customer. The units will be used for multiple smaller projects to be installed later this year.

09:47 EDT HCAP Partners leads formation of PAX Health - HCAP Partners announced the acquisitions of Behavioral Medicine Associates, Workers Compensation Psychological Network, and Reservoir Health, merging under PAX Health. The combination of the three businesses under the PAX Health umbrella creates one of the largest behavioral health businesses in the Northeastern U.S. and allows PAX to extend the full continuum of care to patients. HCAP's Tim Bubnack, Brian Kinsman, Stefan Okhuysen, and Ben Consoli led the transaction. Funds managed by leading private markets investment management firm, Hamilton Lane, joined HCAP in the transaction as a co-investor. Terms of the investment were not disclosed.

09:47 EDT Heritage Insurance rises 24.3% - Heritage Insurance is up 24.3%, or $1.74 to $8.89.

09:47 EDT Gold Fields falls -5.8% - Gold Fields is down -5.8%, or -91c to $14.88.

09:47 EDT On Holding falls -13.7% - On Holding is down -13.7%, or -$4.62 to $29.00.

09:45 EDT Steakholder Foods receives initial SIIRD grant payment - Steakholder Foods has received a first-phase payment ofR220,000 from the Singapore-Israel Industrial R&D Foundation, out of a maximum $1,000,000 for the Company from SIIRD.

09:42 EDT Healthcare Triangle names Anand Kumar as interim CEO - Healthcare Triangle has announced the appointment of Anand Kumar as the interim CEO alongside his current role as the Chief Revenue Officer.

09:42 EDT Power & Digital Infrstre Aqstn II Corp trading halted, volatility trading pause

09:40 EDT Bioventus trading resumes

09:35 EDT Biotricity announces expansion of Cardiac AI Cloud platform - Biotricity announces expansion of its Cardiac AI Cloud platform: the company is building a cardiac AI clinical model which distills important information to support clinician in cases that require clinical intervention or review. The company expects to file an FDA clearance for its clinical model by the end of the year. The healthcare AI market is projected to soar to $208.2 billion by 2030 per Grand View Research. With a projected market value of $96.67 billion by 2030, about 30 million patients are currently enrolled in remote patient monitoring, creating vast quantities of data for clinicians. That number is anticipated to surge to 70.6 billion by 2025, exponentially increasing the data quantity. Biotricity expects its state-of-the-art solutions, fueled by its future Cardiac AI Cloud platform, to empower healthcare professionals in the face of increasing resource shortages and a growing chronically ill population. Providers will be enabled by the Company's revolutionary technology to manage significantly larger patient volumes while being alerted to critical data. This expands the reach of healthcare services to a broader audience, bridging medical accessibility gaps like never before. Already deployed, Biotricity's AI automation engine has demonstrated its effectiveness in increasing operational efficiency while supporting growth. This effectiveness of Biotricity's approach can already be seen in the company's continually improving margins. The company plans to continue to expand its automation engine alongside the development of its clinical engine. Biotricity is expanding its proprietary cardiac AI clinical model with key partner technologies, including Google's TensorFlow and Amazon Web Services infrastructure. By harnessing the power of big data and continuous learning engines, the Company is advancing to new heights. Biotricity's focus is now on expanding data capabilities to develop predictive analytics for early detection, preventing the onset of cardiac conditions, and, if heart disease is developed, mitigating adverse events. Through the analysis of our anonymized data set comprised of over 500 billion heartbeats and once FDA cleared, the Company's new AI clinical model is poised to enhance diagnostic accuracy, optimize treatment plans, and significantly improve patient outcomes. Biotricity anticipates filing for FDA clearance for this groundbreaking AI clinical model later this year.

09:34 EDT Sigma Additive Solutions announces transition to NextTrip - Sigma Additive Solutions announced that, effective Wednesday, March 13, 2024, it will change its corporate name to, and begin operating as, "NextTrip, Inc.", reflecting the transition of the Company following its acquisition of NextTrip Holdings, Inc., a travel technology company based in Sunrise, Florida. In conjunction with the change, the Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "NTRP", effective at the open of market trading on March 13, 2024. All stock trading, filings and market-related information will be reported under the new stock symbol going forward. No action is required from Sigma's stockholders and the CUSIP number for the Company's common stock will remain unchanged. The Company has also changed its corporate web address to www.nexttrip.com.

09:32 EDT Ondas' American Robotics partners with Senhive - Ondas Holdings announced that its wholly owned subsidiary American Robotics announced a strategic partnership with Belgium-based Senhive. This partnership represents a significant milestone for both companies, enhancing their product and service offerings and advancing safe and autonomous uncrewed aircraft systems operations across defense, government, and commercial sectors. The collaboration between American Robotics and Senhive enables integrated autonomous drone operations, incorporating cutting-edge Detect and Avoid, airspace safety and surveillance, and Counter Unmanned Aircraft Systems solutions. Senhive products are trusted and used throughout the world and have been selected to provide airspace security and safety in Europe's biggest harbors like the Port of Antwerp, as well as in locations spanning from Antarctica to significant global events hosting millions of people.

09:30 EDT Performance Shipping secures five-year time charter contracts - Performance Shipping announced that, through separate wholly-owned subsidiaries, it has entered into time charter contracts with Clearlake Shipping Pte for the previously announced three newbuilding LNG-ready, scrubber-fitted, LR2 Aframax tanker vessels. Each employment will be for a firm period of 5 years with the option to extend for a 6th and 7th year. The optional periods are to be declared by the Charterer 12 months in advance. The gross charter rate will be US$31,000 per vessel per day for the firm period of five years, and a base rate plus profit share for the optional periods, if declared. Employment is expected to commence upon delivery of the vessels to the Company in the fourth quarter of 2025, the first quarter of 2026, and the second quarter of 2026.

09:29 EDT Echo Lake calls for firing of NeuroMetrix CEO Shai Gozani - Echo Lake Capital sent a letter to the Board of Directors of Neurometrix. The firm said, "The letter listed the top ten reasons why the Board should immediately fire Shai Gozani, the company's longstanding Chairman and CEO. The reasons include NURO's stock price has declined 99% since the IPO, while shareholders have suffered massive losses, Gozani has received over $10 million of compensation, Gozani was charged by the Federal Trade Commission for various wrongdoings at NURO, Gozani apparently personally paid $4 million to the FTC as part of a settlement, and Gozani's decision to dilute shareholders by having NURO issue shares at prices significantly below net cash. The letter also questions why the Board continue to support Gozani considering his performance over the past twenty years."

09:26 EDT SOBR Safe launches behavioral health webinar series - SOBR Safe has launched a new behavioral health webinar series, featuring industry leaders and cutting-edge best practices. The first webinar, entitled "The Future of Alcohol Monitoring is Here: Discover Touch-Based Detection with SOBRsafe", is scheduled for Wednesday, March 27 at 3:00pm Eastern, 12:00pm Pacific

09:24 EDT Encore Capital announces proposed senior secured notes offering - Encore Capital Group announced its intention to offer, subject to market and other conditions, $400.0 million aggregate principal amount of senior secured notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended and outside the United States to non-U.S. persons. The notes will be senior secured obligations of the Company, and will be fully and unconditionally guaranteed on a senior secured basis by substantially all material subsidiaries of the Company. The obligations of the Company and the guarantors will be secured, together with the Company's other senior secured indebtedness, by substantially all of the assets of the Company and the guarantors. The interest rate and other terms of the notes will be determined at the pricing of the offering. The Company intends to use the proceeds from this offering to repay drawings under its revolving credit facility and to pay certain transaction fees and expenses incurred in connection with the offering of the notes. The Company currently intends to use borrowings under the Global Senior Facility or other available sources of financing to redeem its GBP 300.0 million senior secured notes due 2026 on or about November 15, 2024.

09:23 EDT Paramount up 6% after Axios report on Apollo Global deal inquiry - Shares of Paramount Global (PARA) are up 71c, or 6%, to $12.33 in pre-market trading after Axios' Sara Fischer reported that Apollo Global Management (APO) has reached out in recent days to a special committee formed by Paramount about a possible takeover or asset purchase.

09:21 EDT Workhorse Group not providing annual revenue, unit guidance at this time - "Workhorse is entering 2024 with strong production and delivery capabilities as well as a keen focus on financial discipline and cost control," said Workhorse CFO Bob Ginnan. "As we speak, we are working hard to resolve our short-term liquidity issues described in our 10-K. Over the year, we will maintain our focus on operational excellence and cost reduction as we increase production and expand delivery of our commercial vehicles to meet our financial targets for 2024. At the same time, we will continue to evaluate opportunities to strengthen our financial position and ensure we have the runway to achieve our goals. Given the number of key customer demonstrations underway in Q1 2024, we will report on our progress when it occurs, and, as a result, will not be providing specific annual revenue or unit guidance at this time."

09:18 EDT GoPro partners with Professional Association of Diving Instructors - GoPro and PADI - Professional Association of Diving Instructors - announced the GoPro PADI Distinctive Specialty Course, a new GoPro-specific specialty certification for certified scuba divers, providing training on how to use GoPro cameras, accessories and the Quik video editing app. PADI is the largest purpose-driven diving organization with a global network of 6,600 dive centers and resorts. With the GoPro PADI Distinctive Specialty Course, divers will learn how to use GoPro cameras, accessories and mounts to capture photos and videos both above and beneath the surface, enhance storytelling techniques, edit and share content using the GoPro Quik video editing app. GoPro subscribers will receive 15% off PADI's core Open Water Diver, Advanced Open Water, and Rescue Diver eLearning courses through December 31. GoPro is offering PADI Club members a 3-month free trial to the GoPro Quik video editing app.

09:17 EDT Archer Daniels has engaged third party experts to find Nutrition improvements

09:16 EDT Frontier Group introduces new UpFront Plus seating - Frontier Airlines announced the introduction of UpFront Plus, a new upgraded seating option with extra space and comfort in the first two rows of the aircraft. Customers in UpFront Plus will enjoy a window or aisle seat with extra legroom and a guaranteed empty middle seat, providing additional personal space and comfort at an exceptional value. Starting today, customers can upgrade to UpFront Plus seating for flights departing on or after April 10, 2024, by reserving seats on the Frontier mobile app or at FlyFrontier.com. As a special introductory offer, UpFront Plus seating upgrades will be available starting at only $49 per passenger, per flight segment for travel between April 10 and April 30, 2024, when purchased by March 20, 2024. Seats are limited and restrictions apply.

09:14 EDT Matterport partners with Resi for home extension surveys - Matterport announced that Resi has made Matterport's Pro3 and Digital Twin Platform its technology of choice for surveying homes. Founded in 2016 with the vision of opening up fast, affordable, high-quality architectural services for every UK home, Resi is the UK's leading home extension company having completed more than 7,000 projects to date. In design and construction, inaccurate or incomplete documentation is responsible for an estimated 48% of rework, making accurate measurements vital to set a project up for success.1 To improve accuracy, productivity and quality, Resi explored several laser scanning providers, determining Matterport's Pro3 was its preferred surveying solution due to its scalability and price.

09:14 EDT Sharecare says independent special committee reviewing multiple poposals - Sharecare has been evaluating a range of options including a potential sale of the Company, as well as a reevaluation of potential carveout divestitures and an assessment of Sharecare's strategic direction and continuation as a standalone public company. Sharecare has been interacting with interested parties, and the Board of Directors formed a special committee of independent directors to evaluate multiple proposals for a potential sale transaction and alternatives thereto. Financial and legal advisors have been retained to assist in the evaluation process. "Given the disconnect between Sharecare's stock price and the intrinsic value of our company, we believe engaging with parties who have expressed interest in acquiring us is a prudent approach in our efforts to maximize value for our shareholders," said Jeff Arnold, executive chairman and founder of Sharecare. "The board is committed to taking whatever action is in the best interests of shareholders while management continues to be fully committed to the satisfaction of our customers and executing on our strategy and growth plans." No definitive decisions have been reached regarding strategic alternatives and there is no assurance if or when a transaction may occur. Sharecare will provide an update during its earnings call scheduled for Thursday, March 28, 2024.

09:12 EDT Sharecare reschedules issuance of Q4, 2023 earnings - Sharecare announced that it has postponed the release of its financial results and conference call related to the fourth quarter and full year ended December 31, 2023, which had previously been scheduled for March 13, 2024. Sharecare expects to issue its fourth quarter and full year 2023 financial results after market close on Thursday, March 28, 2024, and hold its conference call on the same day at 4:30 p.m. EDT. In connection with this postponement, the Company will file a Form 12b-25 with the Securities and Exchange Commission to disclose that it will not be able to file its Form 10-K by its due date of March 15, 2024, but it is expected to do so within the 15-day extension period allowed by the Form. For the avoidance of doubt, the Company does not currently expect any changes to previously reported financials.

09:11 EDT T2 Biosystems receives extension to comply with Nasdaq listing requirement - T2 Biosystems announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq Stock Market, subject to the Company demonstrating compliance with Nasdaq's market value of listed securities requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) on or before May 20, 2024. The Company continues to prioritize maintaining its Nasdaq listing and considers it to be in the best interest of both the Company and its stockholders. Listing on the Nasdaq Stock Market maintains liquidity for stockholders, helps attract and retain key employees, broadens its access to capital, and better positions the Company for potential mergers and acquisitions. The Rule requires that the Company maintain a closing Market Value of at least $35.0 million for a minimum of ten consecutive business days. During the extension period, the Company will continue to actively monitor its Market Value and take appropriate action, if necessary and as advised by the Company's Board of Directors, to remedy the deficiency. These actions may include the potential conversion of $15.0 million dollars of outstanding indebtedness held by the Company's lender, CRG, to equity in the Company. There can be no assurance, however, that the Company will be able to timely comply with the terms of the Nasdaq Hearings Panel's decision.

09:09 EDT Constellium announces industrial testing of hydrogen use in casthouses - Constellium announced its move towards industrial testing of hydrogen utilization in its casthouses, marking a significant step in its commitment to decarbonizing its operations. Recycling and casting are the most energy intensive operations and represent close to 50% of Constellium's direct greenhouse gas emissions. Building upon successful laboratory-scale trials conducted in 2022 by C-TEC, Constellium's main R&D center, the Company was able to demonstrate that transitioning from natural gas to hydrogen has no adverse effects on energy efficiency, oxidation rate, or product quality, with a focus on ensuring safe operations. This first demonstration phase has paved the way for industrial-scale testing at C-TEC. In preparation of the industrial testing phase, C-TEC has equipped one of its furnaces with a highly efficient burner capable of operating with oxygen and both natural gas and/or hydrogen. First results are expected Q3 2024.

09:08 EDT Mangoceuticals officially launches 'PRIME' by MangoRx - Mangoceuticals announced the release and availability of 'PRIME' by MangoRx, Powered by Kyzatrex bringing the FDA-approved oral testosterone replacement therapy treatment to consumers across the U.S via its proprietary telehealth platform. MangoRx intends to market PRIME to those male individuals who are both a) currently on some alternative form of TRT treatment, such as topicals and other invasive injectables or pellets, and b) those experiencing common symptoms associated with low testosterone and seeking an immediate TRT treatment.

09:05 EDT Castor Maritime completes sale of M/V Magic Nova - Castor Maritime completed the previously announced sale of the M/V Magic Nova, a 2010-built Panamax bulk carrier vessel, for a price of $16.1 million, by delivering the vessel to its new owner. The Company expects to record a net gain of approximately $4.4 million from the above-mentioned sale, excluding any transaction-related costs during the first quarter of 2024.

09:04 EDT Archer Daniels: Internal investigation 'substantially complete' - Comments taken from Q4 earnings conference call.

09:03 EDT LiqTech awarded first order U.S.-based oil & gas produced water order - LiqTech received a significant order for a containerized pilot system for produced water treatment from Razorback Direct Oilfield, a Houston based company providing water treatment solutions consultancy for oil & gas water treatment in the U.S. This order becomes the first U.S.-based oil & gas produced water order for LiqTech. In February, LiqTech entered into a distribution agreement with Razorback Direct to commercialize its produced water treatment filtration for re-injection and reuse, as well as lithium harvest in the U.S. including Texas, Oklahoma, Louisiana, Ohio, and Pennsylvania. Longer term, the strategic intention is to use the results from this pilot operation as the basis to design and implement full-scale commercial systems for the onshore oil & gas application in the U.S. The newly formed collaboration with LiqTech, along with the recent order, enhances Razorback Direct's produced water treatment value proposition by bringing complementary ceramic ultrafiltration technology to customers.

09:01 EDT Helius Medical initiates open-label study for registrational program in stroke - Helius Medical Technologies announced the initiation of an open-label study for its registrational program in stroke. The program was established based on encouraging early trial results as well as real-world evidence from Canada, where PoNS is already authorized for treatment of stroke, and aims to establish the effects of cranial-nerve non-invasive neuromodulation, delivered using PoNS Therapy, on gait and dynamic balance in chronic stroke survivors. Under the direction of Mark Bowden, PT, PhD, Brooks Rehabilitation will be the first site to enroll patients. Brooks Rehabilitation is already a participant site to the Company's ongoing investigator-initiated, placebo-controlled study in stroke, led by Dr. Steven Kautz at the Medical University of South Carolina.

08:57 EDT Thumzup surpasses 18,000 paid posts through Adtech platform - Thumzup has surpassed 18,000 paid posts on its proprietary social media AdTech platform. This milestone illustrates the vibrant engagement of the Thumzup community, which has collectively earned over $180,000, demonstrating the platform's significant impact and value.

08:55 EDT Fractyl Health announces results from Rejuva platform - Fractyl Health announced new preclinical findings for the first clinical candidate in its Rejuvapancreatic gene therapy platform. RJVA-001 is the Company's first GLP-1 gene therapy candidate to emerge from the platform, setting the stage for a potentially transformative approach to treating metabolic diseases, including obesity and T2D. These results show that the human GLP-1 coding sequence of RJVA-001 demonstrates potency on both glucose lowering and weight loss in db/db mice, the standard rodent T2D efficacy model used for clinical development. The Company has reached alignment with European regulators on the use of this efficacy model to support the submission of a Clinical Trial Application in Europe. Fractyl Health anticipates progressing RJVA-001 through IND-enabling toxicity studies in 2024 and initiating First-in-Human clinical studies in 2025.

08:52 EDT Hudson Global acquires Executive Solutions, terms not disclosed - Hudson RPO announced its acquisition of Executive Solutions, a Dubai-based talent solutions company. This acquisition provides the Company access to the large and rapidly growing United Arab Emirates market and is expected to close later this month. Following the completion of the acquisition, Executive Solutions will be named "Executive Solutions: A Hudson RPO company."

08:51 EDT Cumulus Media announces extension of early tender time in exchange offer - Cumulus Media announced that its subsidiary, Cumulus Media New Holdings, has extended the Early Tender Time in its previously-announced Exchange Offer and Consent Solicitation, in which the Issuer offered to exchange any and all of the Issuer's outstanding 6.750% Senior Secured First-Lien Notes due 2026 for new 8.750% Senior Secured First-Lien Notes due 2029 to be issued by the Issuer, upon the terms of and subject to the conditions set forth in the confidential offering memorandum and consent solicitation statement dated February 27, 2024. Capitalized terms used but not defined in this press release have the respective meanings ascribed to such terms in the Offering Memorandum. The Issuer is extending the previously announced Early Tender Time, which was 5:00 p.m., New York City Time, on March 11, 2024, to 5:00 p.m., New York City Time, on March 18, 2024 The deadline to validly withdraw tenders of the Old Notes was not extended and expired at 5:00 p.m., New York City Time, on March 11, 2024. The Exchange Offer and Consent Solicitation will expire at 5:00 p.m., New York City Time, on March 26, 2024 unless extended or terminated. The New Early Tender Time and Expiration Time are both subject to earlier termination, withdrawal or extension by the Issuer in its sole and absolute discretion. All other terms of the tender offer remain unchanged.

08:49 EDT 3D Systems announces Wilting adds three DMP Flex 350 printers to floor - 3D Systems announced that Wilting has added two single laser DMP Flex 350 and one DMP Flex 350 Dual metal 3D printers to its manufacturing floor. Wilting has experienced significant growth in its business, and these new printers will help address both the increased production capacity and broader materials portfolio required by its customers. The installation of these three DMP Flex 350 systems, alongside the two that are already in use, will enable Wilting to dedicate printers to specific materials such as Titanium and Stainless Steel for 24/7 production of highly precise end-use parts.

08:46 EDT Quisitive Technology to launch MazikCare Copilot at HIMSS Conference - Quisitive Technology Solutions announced the upcoming launch of MazikCare copilot, an AI-powered healthcare solution set to redefine collaboration and productivity in the healthcare industry. Previewing at the annual HIMSS conference in Orlando, Florida, this week from March 11-15. MazikCare copilot is scheduled for general release in April 2024 and represents a significant leap forward in care coordination. In today's healthcare landscape, physicians and care teams face an overwhelming burden of administrative tasks, contributing to burnout and compromising patient care. Since the onset of the COVID-19 pandemic, the demand for healthcare services has surged, exacerbating these challenges. Patient messaging alone has increased by a staggering 157%, further straining care providers. MazikCare copilot is engineered to alleviate this burden by streamlining workflows and automating redundant tasks, empowering healthcare professionals to focus more on patient care and less on paperwork.

08:45 EDT VERB's MARKET.live adds fifty more retail brands - Verb Technology continues the expansion of its MARKET.live livestream social shopping platform with the addition of FIFTY more innovative brands.

08:43 EDT Atossa Therapeutics appoints Tessa Cigler to board of directors - Atossa Therapeutics announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa's board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City.

08:42 EDT Grom Social announces May release of COPPA-compliant Grom Social app - Grom Social Enterprises announced the early May launch of its completely redesigned COPPA-compliant social media app just for kids, Grom Social. The culmination of several months of redesigning its interface and sign-up process, the new Grom app places primary emphasis on several new features to further ensure the safety of its users while boasting fun to both engage kids and educate them about the growing importance of embracing digital safety habits at a young age. The new Grom app will debut in iOS beginning in early May, with the updated interface for Android users slated to premiere at a later date. The updated Grom Social app comes with a brand-new look, feel, and experience with all the safety integrations today's kids deserve and need. Existing users and their parents will migrate from the current experience to immediately enjoy Grom's exciting new environment and interface. Leading the new safety features will be a new parent-child video verification process that ensures that parents and caregivers have granted consent to their child. Additionally, Grom's new 3D avatar asset library allows kids to create their own profile avatar using hundreds of assets featuring a variety of complexions, hairstyles, clothing, accessories, animations, and more. The app's new state-of-the-art camera allows users to create and post videos utilizing the latest in augmented reality technology.

08:40 EDT SHF Holdings originates $4.6M credit facility for Michigan cannabis operator - SHF Holdings originated a $4.6 million credit facility for a Michigan cannabis operator secured by a four-dispensary real estate portfolio. Structured with a market-leading rate and terms, the credit facility will allow the vertically integrated operator to expand its cultivation and retail operations in the Great Lake State. With this new credit facility, Safe Harbor's total loan book will exceed $60 million in outstanding loans and commitments, showcasing the rapid growth of its robust and highly diversified loan portfolio, which is comprised of 25 cannabis real estate assets across 10 states covering every segment of the cannabis value chain.

08:39 EDT SciSparc says MitoCareX reveals millions of small molecules virtually screened - SciSparc announced that MitoCareX Bio, the Company's venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, revealed that millions of small molecules were virtually screened using its computationally advanced drug discovery platform, with several molecules identified as potential anti-cancer treatments. By using its in-vitro screening systems related to the mitochondria, MitoCareX corroborated its virtual findings by confirming the anti-cancer biological activity of several small molecule structures. Additionally, by utilizing the extensive virtual data generated, MitoCareX working towards creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest.

08:36 EDT Cencora CEO Steven Collis to retire, Robert Mauch to succeed - Cencora announced that Steven Collis will retire as president and CEO of the company and transition to the role of executive chair of the Cencora board of directors, effective October 1. Robert Mauch, current COO of Cencora, will succeed Collis as president and CEO, and will also be appointed as a member of the company's board, effective the same date.

08:36 EDT Mainz Biomed presents ColoAlert at UDH Congress 2024 - Mainz Biomed announced its upcoming participation at the 39th UDH Congress 2024, taking place on March 16th & 17th in Fellbach, Germany. One of the main focus topics for this year's event, organized by the German Complementary Medicine Association, is the gut and its significance in the manifestation of diseases. Mainz Biomed's showcase at the UDH Congress underscores the Company's dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices. Mainz Biomed's engagement reflects a deep respect for the diverse methodologies within the healthcare community, emphasizing the commitment to contributing evidence-based, innovative solutions like ColoAlert.

08:35 EDT Claire's Holdings announces national launch in Walgreens Boots Alliance - Claire's Holdings announces a collaboration with Walgreens to bring the brand's assortment of fashion accessories and products to more than 4,400 Walgreens locations nationwide by the end of this month. Through this launch, Claire's best-selling jewelry, hair accessories and cosmetics, as well as seasonal pieces, will now be accessible to even more shoppers, bringing them the products they love at the convenience of their nearest Walgreens. Each participating Walgreens location will have a dedicated display of trend-forward products located within the seasonal section of the store that are merchandised by Claire's.

08:33 EDT IceCure Medical receives Notice of Allowance from Japan Patent Office - IceCure Medical announced it has received a Notice of Allowance from the Japan Patent Office for its patent application titled "Cryogen Flow Control". Once granted, the patent will be in effect until 2042. A patent for this invention is pending approval in European Union, the U.S., and other major markets.

08:32 EDT T. Rowe Price reports preliminary AUM $1.51T at February 29 - T. Rowe Price Group reported preliminary month-end assets under management of $1.51T as of February 29. Preliminary net outflows for February were $2B.

08:29 EDT Tempest Therapeutics presents new data on TPST-1120 at SITC meeting - Tempest Therapeutics announced a poster presentation at the Society for Immunotherapy of Cancer 2024 Spring Scientific Meeting highlighting preclinical data showing potent anti-tumor activity in several cancer models treated with TPST-1120 alone or with immune checkpoint inhibitors. The presentation covered experimental results that corroborated clinical biomarker data from patients with advanced solid tumor cancers treated in a Phase 1 trial with TPST-1120 showing increased expression of select immune-related genes and elevated plasma Free Fatty Acid levels associated with clinical response. TPST-1120 is an oral, selective PPAR antagonist in clinical development that has shown promising results, including positive data from a randomized study in first-line hepatocellular carcinoma patients compared to the standard of care. In preclinical models of liver, colon and pancreatic cancer, TPST-1120 elicited a greater than 50% inhibition of tumor growth with enhanced inhibition observed in liver and colon cancer models when co-administered with anti-PD-1. In addition, biomarker results from the Phase 1 clinical trial of TPST-1120 in multiple solid tumor indications showed statistically significant, exposure-dependent elevations in expression levels of multiple immune-related genes, and patients exhibiting objective responses displayed increased circulating free fatty acids, both of which are in-line with the proposed TPST-1120 mechanism of action. Clinical response and biomarker findings support that inhibition of PPARalpha may be an effective therapeutic strategy for the treatment of cancer. These findings complement positive data reported in October 2023 from a global randomized phase 1b/2 study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC. The differentiating data showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations when compared to atezolizumab and bevacizumab alone, the standard of care in first-line HCC.

08:25 EDT Kratos Defense to deploy self-driving Class 8 trailers in Ohio, Indiana - Kratos Defense & Security Solutions will be deploying self-driving Class 8 tractor/trailers in a Leader Follower Platoon hauling customer freight shipments along revenue generating routes in Ohio and Indiana. The Kratos Unmanned Systems Division is under contract to deploy its self-driving platooning technology later this year between Ohio and Indiana along a major trucking corridor. Teamed with EASE Logistics, the Leader Follower Platoon will be a first-of-its kind deployment to address driver shortage impacts by enabling business continuity when qualified drivers are unavailable. The leader and follower trucks were provided by EASE Logistics who will also provide a highly qualified driver for the leader truck and a Safety Rider onboard the self-driving follower truck who can take over manual driving control at any time. The trucks were retrofitted by Kratos with self-driving technology to enable the Leader Follower Platooning operation. The system will be integrated as part of normal 24/7 supply chain activity hauling freight in 53-foot dry van trailers on short-haul routes for round-trip totals of 450 to 500 miles.

08:23 EDT Philips, AWS collaborate to scale digital pathology in the cloud - Royal Philips (PHG) announced an expanded collaboration with Amazon Web Services (AMZN) to address the growing need for secure, scalable digital pathology solutions in the cloud. The collaboration unites Philips' leadership and expertise in digitization of pathology to optimize clinical workflows and AWS' leadership in scalable, secure cloud solutions. Philips and AWS will advance digital pathology and help pathology labs to efficiently store, manage, and analyze growing volumes of digital pathology data and enable more pathology labs to adopt digital workflows to increase productivity. In addition, pathology labs will be able to optimize workflow efficiency and facilitate collaboration among specialists, enabling seamless integration with existing healthcare systems to deliver holistic patient care.

08:19 EDT NewAmsterdam Pharma doses first patient in Phase 3 TANDEM trial - NewAmsterdam Pharma announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies. The primary objective of the placebo-controlled, double-blind, four-arm, randomized TANDEM trial is to evaluate the effect of 10mg obicetrapib and 10mg ezetimibe FDC on LDL-C levels, compared to both ezetimibe 10mg and obicetrapib 10mg monotherapy and to placebo. Secondary objectives include evaluating the effect of the FDC on apolipoprotein B and non-high-density lipoprotein cholesterol. The trial will also evaluate the safety and tolerability profile of the FDC. NewAmsterdam anticipates enrolling approximately 400 patients on maximally tolerated lipid-modifying therapies with HeFH, ASCVD or ASCVD risk equivalents and who have a baseline LDL-C of at least 70 mg/Dl. Patients will be randomized to one of the following groups: placebo, 10 mg obicetrapib, 10mg ezetimibe, or obicetrapib 10mg and ezetimibe 10mg FDC tablet, all groups dosed as a once-daily oral treatment for an 84-day treatment period. HeFH is an inherited genetic disorder that causes dangerously high cholesterol levels. Patients with ASCVD have established cardiovascular diseases characterized by the buildup of plaque in the arteries, including coronary artery stenosis, myocardial infarction or stroke. Patients who have multiple risk factors for ASCVD are at high risk of experiencing a cardiovascular event in the near future.

08:17 EDT Veru appoints Louis Arrone as chief medical advisor for Enobosarm program - Veru announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator, to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist drug for potentially higher quality weight loss. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center, a state-of-the-art, multidisciplinary obesity research, education, and treatment center in the division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine.

08:16 EDT Provectus announces notice of allowance, award for U.S. patents - Provectus Biopharmaceuticals announced that the United States Patent and Trademark Office has allowed patent application 17/212,723, titled "Novel Uses of Halogenated Xanthenes in Oncology and Virology." The application covers the use of Provectus's pharmaceutical-grade rose bengal sodium drug substance for the treatment of infectious diseases, such as coronaviruses. The USPTO has also allowed patent application 17/344,418, titled "In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors." This prospective award covers the use of RBS in combination with one or more immune checkpoint inhibitors and is a continuation of U.S. patent 11,058,664, Provectus's first for pediatric oncology. The Company's previously allowed patent application 17/488,430, titled "Halogenated Xanthenes as Vaccine Adjuvants" and covering RBS's use as an adjuvant in vaccines to potentially make them work better, will be awarded on March 26, 2024 as U.S. patent 11,938,182. Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University's Cumming School of Medicine is a co-inventor on all three patent awards.

08:15 EDT Inspired Entertainment launches Virtual Sports content in New Jersey - Inspired Entertainment (INSE) announced the launch of its Virtual Sports content in New Jersey through a partnership with Rush Street Interactive (RSI). Inspired's Virtual Sports content is now accessible to BetRivers players through its renowned BetRivers sportsbook and casino, providing players in New Jersey an engaging experience. This launch is the first of many planned across other states with RSI in the coming year.

08:13 EDT 89bio initiates Phase 3 ENLIGHTEN-Fibrosis trial of pegozafermin - 89bio announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis. ENLIGHTEN-Fibrosis, the first of two Phase 3 trials in the program, has initiated and is evaluating non-cirrhotic MASH patients with fibrosis stage F2-F3. ENLIGHTEN-Fibrosis is a global Phase 3, randomized, double-blind, placebo-controlled trial of pegozafermin for the treatment of patients with biopsy-confirmed non-cirrhotic MASH. Approximately 1,000 patients are expected to be randomized in a 1:1:1 ratio to receive either 30mg of pegozafermin administered weekly, 44mg administered every two weeks, or placebo. The co-primary endpoints are a one-point or greater improvement in fibrosis with no worsening of MASH, and MASH resolution with no worsening of fibrosis. The co-primary endpoints will be assessed at week 52 and are intended to support a filing for accelerated approval in the U.S. and conditional approval in Europe in non-cirrhotic patients. Patients are expected to continue to be treated beyond the 52-week assessment through outcomes to support full approval. Key secondary endpoints include additional histological endpoints, noninvasive tests and metabolic and lipid assessments. The trial is designed to employ a three-panel consensus biopsy reading methodology, which was successfully utilized in the ENLIVEN trial. Patients will self-administer pegozafermin using the planned commercial liquid formulation delivered as a single subcutaneous injection.

08:10 EDT Galectin Therapeutics appoints Khurram Jamil as VP, clinical development - Galectin announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Prior to joining Galectin, Dr. Jamil was the Vice President Hepatology in the critical care division of Mallinckrodt Pharmaceuticals.

08:09 EDT Polar Power announces $5.1M in new bookings to date in Q1 - Polar Power announces approximately $2.5 million in additional new bookings from both military and telecom customers. Combined with the $2.9 million in previously announced new bookings in January, Polar Power has announced $5.4 million in new bookings for the first quarter of 2024, which compares to $3.7 million in new bookings for the first quarter in 2023, an increase of 46%.

08:08 EDT ARPA-E awards Booz Allen $550M contract to support energy technology innovation - Booz Allen Hamilton announced it was awarded a ten-year $550M contract from the U.S. Department of Energy's Advanced Research Projects Agency-Energy, ARPA-E, to support the advancement of high-potential, high-impact, early-stage technologies that generate, store, and use energy in entirely new ways to reduce U.S. emissions, improve energy efficiency, and increase the resiliency and reliability of the U.S. power grid. Booz Allen was instrumental in the stand up of ARPA-E in 2009 and has been a key mission partner since Day One. The company serves as primary technical and operations support to ARPA-E-an organization that, in the words of its first director Dr. Arun Majumdar, was tasked with identifying, shepherding, and accelerating "...the stuff that sounds crazy until it changes the world." A funding and technology agency, ARPA-E will be supported under this contract by Booz Allen to help identify energy mission needs, support an innovation ecosystem to drive emerging technology that promises to meet the nation's energy goals-but that is too nascent for private sector investment-and then de-risk it in order to secure long-term funding and deployment for impact. This work draws from Booz Allen's more than 50 years of support for government ARPA programs, including for health ARPA-H , intelligence (IARPA) and defense DARPA; and more than 10 years specifically supporting ARPA-E; in addition to Booz Allen's own corporate venture capital arm, Booz Allen Ventures, which identifies and invests in early-stage technology poised to transform mission outcomes for the public sector. "We are proud to be ARPA-E's partner in powering the critical mission to enhance the U.S. competitive position in science and technology, improve environmental wellbeing, and solve the most pressing climate challenges using novel technology," said Mike Miller, leader of the company's ARPA-E work and its broader civilian energy business. "Booz Allen empowers its people to change the world, and our team is doing just that-upsetting the status quo in energy technology, operating like a startup, and advancing an ecosystem where not-yet-invented technology can rise and be deployed for good."

08:07 EDT iKena Oncology expects cash to meet operating requirements into 2H26 - As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $175.5 million, which the Company believes will be sufficient to fund operations into the second half of 2026.

08:06 EDT Hess Midstream LP announces $100M sponsor unit repurchase - Hess Midstream LP announced the execution of a definitive agreement providing for the repurchase of approximately $100M of Class B units by its subsidiary, Hess Midstream Operations, from affiliates of Hess Corporation and Global Infrastructure Partners, Hess Midstream's sponsors. The terms of the proposed unit repurchase transaction were unanimously approved by the board of directors of Hess Midstream's general partner, based on the unanimous approval and recommendation of its conflicts committee composed solely of independent directors. Pursuant to the terms of the repurchase agreement, the repurchased units will be cancelled upon the closing of the unit repurchase transaction, which is expected to result in increased distributable cash flow per Class A share providing capacity for incremental distribution growth above Hess Midstream's annual distribution target of at least 5% through 2026, consistent with Hess Midstream's return of capital framework.

08:04 EDT Inspira Technologies' Vortx meets 100% requirements for blood oxygenation - Inspira Technologies' U.S. patent backed technology, the orbiting blood oxygenation technology Vortx, has meet 100% of regulatory guideline requirements for blood oxygenation and carbon dioxide removal, at various blood flow rates with the pressure gradient on the blood across the device remaining at zero level. Pressure gradient is associated with high mechanical shear stress - HMSS -, which plays a dominant role in damaging blood components. The experiments demonstrated the primary performance of the Vortx by collecting data on oxygenation, carbon dioxide removal, and pressures across the device during blood use. Performance of the Vortx, tested according to a regulatory guideline, was found to meet 100% of blood oxygenation requirements at various blood flow rates.

08:02 EDT Black Diamond Therapeutics expects cash to fund requirements into 2Q25 - Black Diamond ended 2023 with approximately $131.4 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the second quarter of 2025.

08:01 EDT Jeffs' Brands: Fort Products generates $5.3M from Amazon sales since acquisition - Jeffs' Brands announced preliminary unaudited financial results for Fort Products, its wholly owned subsidiary, on its revenue for sales on Amazon Marketplace, according to the data received from the Amazon seller central. The following results is for the period beginning on March 9, 2023, the date Fort was acquired by the Company, and ending on December 31, 2023. Fort's Amazon generated revenues for the Period, amounted to approximately $5.3 million, representing an increase of 23% compared $4.3 million at the same period of 2022, prior to the acquisition. Profit attributed directly to Amazon sales, amounted to $614 thousand, compared to $445 thousand in the same period of 2022.

07:52 EDT FTI Consulting appoints Jiva Jagtap as global leader, private equity - FTI Consulting announced the appointment of Jiva Jagtap as Global Leader of the firm's Private Equity service offering. Jagtap, who is based in Denver, has more than 25 years of experience advising private equity groups and their portfolio companies, as well as public companies. In his role as Global Leader of the Private Equity service offering at FTI Consulting, he will lead a diversified cross-segment team of professionals across the firm's global network who support private equity clients throughout the transaction lifecycle, from ideation, validation and assessment through transaction execution, value creation and eventual exit.

07:51 EDT Immunovant awarded U.S. patent for IMVT-1402 - Immunovant announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,926,669 for IMVT-1402, the Company's second-generation antibody targeting the neonatal fragment crystallizable receptor. The allowed claims cover composition of matter for the binding sequence of IMVT-1402 to FcRn, method of use of the antibody for treating autoimmune disease, as well as methods for its manufacturing. Not including any potential patent term extension, the '669 patent will expire on June 23, 2043. IMVT-1402 is being developed by Immunovant based on antibody discovery efforts by HanAll Biopharma. IMVT-1402 delivered subcutaneously has demonstrated potentially best-in-class profile in a Phase 1 clinical trial in healthy adults, with initial data demonstrating a deep immunoglobulin G reduction that is similar to batoclimab, but with no or minimal changes in serum albumin and LDL cholesterol, consistent with placebo. Immunovant believes that IMVT-1402 administered weekly can achieve steady reductions in IgG and further believes that steady reductions in IgG lowering are needed to avoid fluctuations in efficacy.

07:48 EDT Pliant Therapeutics announces accelerated bexotegrast development plan - Pliant Therapeutics announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis. The adaptive design implementation, based on acceptance by the European Union and other global health authorities, will significantly shorten bexotegrast's late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of alphavbeta6 and alphavbeta1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis. Following acceptance by the EU and various other global health authorities, the Company is implementing BEACON-IPF as a Phase 2b/3 operationally seamless, adaptive design which includes the ongoing BEACON-IPF Phase 2b trial. Patients will begin enrolling in the Phase 3 component immediately after completion of enrollment of the Phase 2b component of the trial. Because of the seamless design, the power of the Phase 2b will be increased by augmenting the sample size by 90 patients, allowing both components to support potential registration. This increase is expected to have minimal impact on timelines. The Company also announced an amendment to its May 2022 $100 million loan facility with Oxford Finance LLC, upsizing the facility to a total size of $150 million of available non-dilutive capital. This facility, along with the Company's December 31, 2023 cash and cash equivalents of $495.7 million are expected to fund Pliant through 2026.

07:45 EDT Marimed opens bigger Thrive Dispensary in Casey, Illinois - MariMed announced the opening of its permanent and much "bigger" Thrive dispensary in Casey, Illinois. The adult-use dispensary had operated from a temporary location since opening last October. Thrive Casey, the Company's fifth operational dispensary in Illinois, will continue to be managed by MariMed under a Managed Servies Agreement until a license transfer is approved by the Illinois Department of Financial & Professional Regulation. The Company continues to look for additional retail locations in the high-growth state, where adult-use cannabis sales exceeded $1.6 billion last year. Current Illinois cannabis regulations allow a license holder to operate up to 10 dispensaries. MariMed also recently became vertical in Illinois, opening a craft grow and processing facility in Mt. Vernon in December. The Company now distributes most of its products at Thrive dispensaries and through the wholesale channel all over the state.

07:42 EDT Talisker signs ore purchase agreement with New Gold - Talisker Resources announced that the Company, through its 100% owned subsidiary Bralorne Gold Mines has signed a definitive Ore Purchase Agreement with New Gold. As part of the Agreement New Gold will purchase up to 350,000 tonnes of material mined at Bralorne and process it at their mill located at its New Afton mine. The Agreement can be extended by mutual agreement by New Gold and Talisker.

07:40 EDT Revive Therapeutics offers update on research, clinical, regulatory initiatives - Revive Therapeutics announced a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product. The Company is advancing the research and development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID and medical countermeasures, such as nerve agent exposure. Chemical Warfare - Nerve Agent Exposure: Currently, in partnership with Defence R&D Canada - Suffield Research Centre, an agency of the Canadian Department of National Defence, the Company is evaluating Bucillamine as a potential treatment for nerve agent exposure. DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury. Recent studies have shown that antioxidant compounds such as n-acetylcysteine could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed. The results from this research partnership, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces. The research project is expected to be completed by June 2024. Long COVID: Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial in preparing a regulatory and clinical package that includes a proposed Phase 2 clinical study for long COVID to present to the FDA and international health regulatory authorities. The Phase 2 study protocol has been completed, and the Company is preparing its submission to the FDA. It expects to submit it by the end of March 2024. The proposed Phase 2 clinical study is expected to be approved by the FDA in Q2-2024. In addition, Revive may evaluate the potential of its proposed long COVID diagnostic product as a companion to Bucillamine. Long COVID Diagnostic Product: The Company, under its wholly-owned subsidiary Revive Diagnostics Inc., is advancing the product development of a potential blood biomarker diagnostic that characterizes long COVID. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine. The Company entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to the intellectual property of novel blood biomarkers that characterize long COVID. The intellectual property includes PCT/CA2023/050145 entitled "Blood Biomarkers in Long-COVID19"; PCT/CA2023/051292 entitled "Biomarkers in Long-COVID19"; and US Provisional Patent Application No. 63/433,425 entitled "Diagnosis and Treatment of Long-COVID". Revive and Lawson continues to work together in completing the product development and investigational plans of a qELISA laboratory test kit and a point-of-care device for rapid testing of long COVID for FDA review, feedback and acceptability. The Company expects to submit a pre-investigational device exemption meeting package with the FDA in April 2024 and have its meeting with the FDA in early Q3-2024.

07:36 EDT Scholastic to invest in 9 Story Media Group - Scholastic has signed a definitive agreement to invest in 9 Story Media Group. Through the investment, Scholastic will acquire 100% of the economic interest in and a minority of voting rights in 9 Story Media Group, an independent creator, producer and distributor of children's content, for approximately $186M, subject to customary closing adjustments. 9 Story's business divisions include Brown Bag Films animation studio, which has won 21 Emmy awards and two Oscar nominations; 9 Story Distribution International, the global distribution division; and 9 Story Brands, the consumer products division. The investment has been approved by both companies' boards of directors and the shareholders of 9 Story. The transaction is expected to close in Scholastic's 1Q25, which begins on June 1, 2024. Scholastic intends to initially fund the transaction from its available cash and its revolving credit facility and anticipates maintaining its regular dividend and its authorized stock repurchase program. Story recorded revenue of approximately $104M in its most recent fiscal year. Scholastic expects the addition of 9 Story to contribute long-term earnings accretion, reduce the capital intensity of production and drive substantial improvements in top-line growth and bottom-line results.

07:32 EDT FMC Corporation expands biologicals crop protection platform in Canada - FMC Corporation announced a collaboration in Canada with Novonesis, a provider of plant biosolutions. The agreement is part of FMC's strategic plan to grow its biologicals platform in key markets. Beginning June 1, FMC Canada will be the exclusive distributor of Novonesis' biosolution products for the 2025 growing season. Additionally, the companies will utilize their respective R&D capabilities to collaborate on the development of novel biological technology for Canadian farmers. The partnership will leverage Novonesis' Plant Biosolutions Manufacturing and Research site in Saskatoon, Canada, and FMC's market knowledge and expertise in applying biologicals in an integrated approach with synthetic crop protection chemistry and precision agriculture technology. Terms of the commercial agreement were not disclosed.

07:28 EDT Genius Sports named 'Successful Bidder' for football DataCo betting rights - Genius Sports Limited and Football DataCo the data rights holder of English and Scottish football, have entered into an exclusive period of negotiation to extend their official betting data partnership. The agreement remains subject to contract and approval of the Leagues and their respective Clubs. Since 2019, Genius Sports has been DataCo's exclusive supplier of official low latency data from the English Premier League, EPL, English Football League, EFL, and Scottish Professional Football League, SPFL, to the global sports betting industry. The current rights agreement runs until the end of the 2024-2025 season with the new rights cycle being 2025-2029.

07:28 EDT 908 Devices trace chemical identification technology chosen by European agencies - 908 Devices announced the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency, or NSPA, have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry, or HPMS, device. The MX908 will be used in a variety of settings, from military applications to correctional facilities.

07:25 EDT Augmedix announces data, product enhancements for Augmedix Go - Augmedix announced new positive data and product enhancements for Augmedix Go, its ambient AI medical documentation product. Now supporting over 50 medical specialties, the Augmedix Go mobile app optimizes ambient AI technology to produce comprehensive draft medical notes in real time by processing the natural conversations between clinicians and patients. New data from survey responses from more than a dozen enterprise and independent healthcare organizations found that clinicians in ambulatory care settings save up to one hour or more per clinic day by using Augmedix Go. Additionally, 94% of clinicians surveyed reported that Augmedix Go helps them better focus on their patients.

07:25 EDT Laser Photonics receives order for CleanTech LPC-500-CTHD - Laser Photonics announced that it received an order for its CleanTech LPC-500-CTHD laser cleaning system from Komatsu through LPC's Japanese distributor.

07:24 EDT FiscalNote reports strategic review ongoing - Following the announcement of the board's formation of a Special Committee in November and receipt of inbound interest, the board and the committee along with their advisors continue to review the company's ongoing plans and evaluate all strategic value-maximizing options available to the company. There can be no assurance that the strategic review will result in any transaction or other outcome. The company has not set a timetable for completion of the review and does not intend to disclose developments or provide updates on the progress or status of the review unless and until it deems further disclosure is appropriate or required.

07:21 EDT PyroGenesis announces accelerated construction of fumed silica reactor project - PyroGenesis Canada announced that the next milestone for pilot plant development has been reached. The Fumed Silica Reactor technology project is being conducted in conjunction with HPQ Silica Polvere, a wholly owned subsidiary of HPQ. With all major equipment now on site, the construction phase of the 50 tonnes per year FSR pilot plant is accelerating. Fumed silica is a moisture-absorbing white microstructure powder with high surface area and low bulk density. Used most often as a thickening agent, anti-caking agent, and stabilizer to improve the texture and consistency of products, the commercial applications of fumed silica can be found in many industries across thousands of product lines, including - but not limited to - personal care, powdered food, pharmaceuticals, agriculture, adhesives, paints, sealants, construction, batteries and automotive. The FSR converts quartz into fumed silica in a single and eco-friendly step while eliminating the use of harmful chemicals generated by conventional methods. The FSR, if successful, could provide a groundbreaking contribution to the repatriation of silica production to North America. The FSR pilot plant is being constructed within a dedicated space inside PyroGenesis' facilities, with a custom-designed infrastructure that meets the pilot plant's unique ventilation, safety, and access requirements. A 4,000 sq ft facility with a 30-foot height allowance has been allocated to house the pilot plant, which itself has an approximate layout footprint of 50ft by 30ft. The FSR pilot plant is being developed by PyroGenesis with a 50 TPY output capacity.

07:16 EDT Rockwell Automation announces Stephen Ford as chief information security officer - Rockwell Automation (ROK) announced that Stephen Ford is joining the company as vice president and chief information security officer, effective immediately. He will report to Chris Nardecchia, senior vice president and chief information officer at Rockwell Automation. In this role, Ford will develop and execute a holistic cybersecurity strategy to ensure that Rockwell and our Connected Enterprise ecosystem-the company's infrastructure, products, and customers-are safe, secure, and resilient. Ford joins Rockwell from McKesson (MCK).

07:16 EDT GXO Logistics appoints Nizar Trigui as CTO - GXO Logistics announced the newly created leadership role and appointment of Nizar Trigui as Chief Technology Officer to further accelerate GXO's industry leadership in technology and capitalize on the increasing global demand for advanced warehouse solutions. The CTO, reporting to CEO Malcolm Wilson, has responsibility for GXO's global technology function, working with the company's innovation leaders to make cutting-edge technology an integral part of GXO's future growth. Most recently, Trigui served as CEO of Bridgestone Mobility Solutions.

07:13 EDT Blade Air Mobility announces acquisition of eight Hawker 800 aircraft - Announced pending acquisition of eight Hawker 800 aircraft which had previously been 100% dedicated to Blade's Medical business. The $21.0 million acquisition cost will be funded through $11.7 million in cash and $9.3 million in existing deposits with the operator.

07:10 EDT ExcelFin Acquisition and Baird Medical provide update to business combination - ExcelFin Acquisition and Baird Medical, a microwave ablation medical device developer and provider in China and the U.S., announced a strategic update to their previously announced business combination agreement. In December 2021, China's National Medical Products Administration announced that it would subject devices for medical devices intended for human body insertion to the more stringent Class III certification. Baird Medical's Class III certificate was approved in July 2023. Baird Medical is one of only four entities to hold Class III certificates for MWA devices for thyroids. Baird Medical recorded 2023 revenues 29% below its projections. The updated transaction terms were in part driven by Baird Medical's lower than expected 2023 results. Baird Medical aims to increase the percentage of the procedure's expenses eligible for reimbursement. Baird Medical has agreed to subject 30% of the Baird Medical shares to an earnout, with vesting achieved if the volume-weighted average price is greater than or equal to $12.50 over any 20 trading days within a 30-day trading period. Baird Medical has made the strategic decision to waive the previously agreed upon minimum cash condition of $15M.

07:07 EDT Archer Daniels announces additional $2B share repurchase program - ADM also announced the company's board has authorized management to repurchase an additional $2B of the company's shares under ADM's existing 200 million share repurchase program that runs through 2024. The company intends to initiate this capital return utilizing available cash on hand and intends to make approximately $1B of this capital return through an accelerated share repurchase.

07:05 EDT Chicago Atlantic names Peter Sack co-CEO, Phil Silverman CFO - Chicago Atlantic announced two promotions among its senior management team. Peter Sack, formerly Co-President, has been promoted to Co-CEO alongside Tony Cappell. Phil Silverman, formerly Interim CFO, has been promoted to CFO. Both promotions were effective on March 7, 2024.

07:00 EDT CNX Resources reduces FY24 production volume, capital expenditures outlook - CNX Resources announced an operational and guidance update. In response to the continued lower outlook for near term natural gas prices, the company will delay completions activities on three upcoming Marcellus Shale pads consisting of 11 wells to avoid bringing incremental volumes into the current oversupplied market. The company expects 2024 production volumes to be between 540-560 Bcfe, a decrease of approximately 30 Bcfe from the midpoint of the previously stated guidance range. Additionally, the company maintains the flexibility to return to its previously stated long term production volume target of approximately 580 Bcfe in 2025. Total capital expenditures: The company expects 2024 total capital expenditures to be between $525M-$575M, a $50M reduction from the midpoint of the previously stated guidance range.

06:50 EDT OneSpaWorld named exclusive spa provider for Royal Caribbean Royal - OneSpaWorld Holding (OSW) has announced entry into a new agreement with Royal Caribbean International (RCL), that commenced January 1, 2024. This new agreement builds upon the company's more than 30-year relationship with Royal Caribbean International, under which OneSpaWorld will operate and execute a suite of wellness, beauty, acupuncture, medi-spa, and fitness services across the Royal Caribbean International fleet, including Icon of the Seas, Utopia of the Seas, scheduled to arrive in July 2024, Star of the Seas, scheduled for summer 2025, and all other ships that come into service during the partnership.

06:48 EDT Southwest: Boeing advises to expect 46 737-8 aircraft deliveries in 2024 - Regarding timing of expected aircraft deliveries, The Boeing Company (BA) has advised Southwest (LUV) to expect 46 737-8 aircraft deliveries in 2024, a reduction from the Company's previous expectation of 79 737 MAX aircraft deliveries, which included 58 -8 aircraft. Further, the Company now assumes no 737-7 aircraft deliveries and continues to assume no -7 aircraft are placed into service this year based on the current certification status. As a result of Boeing's continued challenges, the Company expects the delivery schedule to be fluid and, therefore, plans to reduce capacity and re-optimize schedules, primarily for the back half of 2024, which will likely result in at least a one point reduction to the Company's full year 2024 capacity plans on a year-over-year basis. As a result, the Company is also reevaluating all prior full year 2024 guidance, including the expectation for capital spending, and plans to provide updated full year 2024 guidance in conjunction with the reporting of its first quarter 2024 financial results on April 25, 2024. The Company is optimistic about the future and remains focused on making continuous adjustments to its operating plan as it works towards its goal of covering the cost of capital and ultimately, in driving towards its long-term goal to consistently achieve after-tax return on invested capital well above the Company's weighted average cost of capital.

06:47 EDT Pfizer's Adcetris shows improved survival in Phase 3 lymphoma trial - Pfizer announced that a Phase 3 study of the antibody-drug conjugate Adcetris in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma - DLBCL - showed a statistically significant and clinically meaningful improvement in overall survival compared to lenalidomide and rituximab plus placebo. Positive outcomes were also observed in key secondary endpoints, including progression free survival and overall response rate. The safety and tolerability of Adcetris in the ECHELON-3 trial were consistent with what has been previously presented for patients with relapsed/refractory DLBCL treated with Adcetris in clinical trials. DLBCL is the most common type of lymphoma and is a fast-growing, aggressive blood cancer. Approximately 40% of patients with DLBCL do not respond to initial treatment or develop relapsed disease after first-line treatment. Adcetris is a standard of care for patients with certain lymphomas and is approved for seven indications in the U.S. Pfizer plans to share the ECHELON-3 data with the FDA to potentially support regulatory filing in the U.S.

06:46 EDT Southwest now sees Q1 RASM flat to up 2% vs. prior up 2.5%-4.5% view - In an update ahead of the J.P. Morgan Industrials Conference, Southwest said: "The Company's first quarter 2024 operational performance has been strong, thus far, and flight cancellations have been lower than was expected in late January, when first quarter 2024 capacity guidance was last provided. Since February 1, 2024, the Company's completion factor has averaged 99.3 percent. Based on this trend, the Company now expects first quarter 2024 capacity to increase approximately 11 percent, compared with its previous estimate of approximately 10 percent, both year-over-year. Further, the Company now expects first quarter 2024 RASM to be in the range of flat to up 2 percent, compared with its previous estimate of up 2.5 percent to 4.5 percent, both year-over-year. Approximately one point of the decrease is due to higher than expected completion factors in February and March, with the remainder primarily attributable to lower than expected close-in leisure passenger volume. Thus far, first quarter 2024 managed business trends continue to strengthen sequentially, in line with expectations. Overall, demand remains stable and network adjustments are accretive. Nominal sequential RASM in first quarter 2024, relative to fourth quarter 2023, is still expected to be higher than seasonally normal and the Company continues to expect record first quarter operating revenues for first quarter 2024. Looking ahead, bookings for second quarter 2024 are currently ahead of seasonally normal trends and the Company expects to deliver all-time record operating revenues for the quarter. The Company expects positive year-over-year RASM trends to continue throughout the year."

06:37 EDT 3M CEO Michael Roman to transition to chairman, William Brown to succeed - 3M (MMM) announced that William Brown is appointed chief executive officer, effective May 1. He succeeds Michael Roman, who is appointed to the role of executive chairman of the 3M Board of Directors, also effective May 1. Brown is the former chairman of the board and CEO of L3Harris Technologies (LHX). Roman will continue to chair 3M's board. He has served as 3M's CEO since July 2018. 3M also announced that the board waived the mandatory retirement age of 65 years for Roman and Brown.

06:35 EDT MediciNova's MN-166 shows efficacy in lung injury study - MediciNova collaborator Perenlei Enkhbaatar, Professor, Department of Anesthesiology, University of Texas Medical Branch, presented new data and results of a nonclinical study evaluating MN-166 - ibudilast - in a chlorine gas-induced acute lung injury - CIALI - model at the Society of Toxicology 63rd Annual Meeting and ToxExpo in Salt Lake City, Utah. The primary objective of this nonclinical efficacy study was to determine the safety and pharmacological activity of MN-166 following ALI induced by chlorine gas inhalation in a clinically relevant translational ovine model. The primary endpoint was the mean change in the pulmonary function measure PaO2/FiO2. Additional endpoints included survival, lung mechanics, lung injury, and edema formation. MN-166 20 mg and rolipram treatment resulted in greater improvement in mean PaO2/FiO2 and peak airway pressure but dissipated after Hour 12. MN-166 20 mg showed greater improvement in mean PaO2/FiO2 ratio. MN-166 20 mg also showed greater improvement in peak airway pressure, plateau airway pressure, pulmonary artery pressure, and lung injury score vs. other treatment groups. MN-166 20 mg also maintained cardiac and kidney function compared to the other treatment groups. MN-166 20 mg treatment demonstrated a greater survival benefit than the other treatment groups. All animals in the MN-166 20 mg group survived the 48-hour monitoring period, while 25% animals were euthanized early in other groups upon reaching the euthanasia criteria.

06:33 EDT Ideaya enters supply agreement with Merck to evaluate IDE161, Keytruda - Ideaya Biosciences (IDYA) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK) to evaluate IDE161, the company's investigational, potential first-in-class, small molecule poly glycohydrolase, or PARG, inhibitor, in combination with Keytruda Merck's anti-PD-1 therapy, in patients with microsatellite instability-, or MSI-, high and microsatellite stable, or MSS, endometrial cancer, in a Phase 1 clinical trial.

06:26 EDT Parsons wins seat on $1B contract supporting DC Metro projects - Parsons was awarded a seat on an indefinite-delivery, indefinite-quantity multiple award task order contract - or MATOC - by the Washington Metropolitan Area Transit Authority for multi-disciplinary project and construction management support. The approximately $1B ceiling-value MATOC includes a base period of five years as well as a one-year option period and represents new work for Parsons. Under this MATOC, Parsons will compete for task orders to provide project management and engineering support services for the authority's capital improvement program.

06:05 EDT Greenwich LifeSciences initiates first clinical sites in Europe - Greenwich LifeSciences initiated the first clinical sites in Europe in collaboration with GEICAM in Spain. The company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 hospitals have agreed to participate in FLAMINGO-01. These sites were recently approved by Spanish authorities, which led to site initiation visits and training of the first sites this past week. Founded in 1995, GEICAM is a not-for-profit organization leading academic breast cancer research in Spain.

06:02 EDT Beam Global receives first European order for EV ARC charging systems - Beam Global announced that it has received its first order from the UK Ministry of Defence for ten EV ARC sustainable electric vehicle charging systems and one ARC Mobility trailer to be deployed at British Sovereign Bases on Cyprus through Project EVOLVE-Rapidly Deployable and Transportable Electric Vehicle Charging Solution per the requirement set out by the Crown Commercial Service Spark Technology Innovation Marketplace Dynamic Purchasing System Agreement. The $1M order was placed through CCS which is the main purchasing vehicle for UK government entities and supports the public sector to achieve maximum commercial value when procuring common goods and services.

05:13 EDT Hyzon launches single stack 200kW fuel cell system, powertrain in Prime Mover - Hyzon launched its single stack 200kW fuel cell system and powertrain in a vehicle at a ceremony attended by government officials, heavy-duty fleet operators and company employees and executives. The vehicle - Hyzon's 200kW Prime Mover, the Australian term for a heavy-duty commercial truck designed to tow a semi-trailer - was officially unveiled at the Kangan Institute's Automotive Centre of Excellence, or ACE, in Melbourne, one of the largest educational providers of automotive training and accreditation in Australia. Sporting the company's refreshed branding, the 200kW Prime Mover reflects Hyzon's commitment to technological advancements and is designed to meet the operational demands of heavy-duty road transport. Hyzon integrated its fuel cell technology and 200kW FCEV powertrain first into a cabover vehicle, a familiar design for fleets in Australia, New Zealand, and Europe. The company expects to deploy 200kW cabovers in Europe and 200kW conventional vehicles in the U.S. later this year.

05:04 EDT NextPlay Technologies receives additional noncompliance notice from Nasdaq - NextPlay Technologies announced the company has received a notice from Nasdaq that it has not held an annual meeting of shareholders within twelve months of the end of the company's fiscal year end, and no longer complies with Nasdaq's Listing Rules for continued listing. The company has not regained compliance with the Annual Meeting Rule. Accordingly, this matter serves as an additional basis for delisting the company's securities from The Nasdaq Stock Market. This notice is formal notification that the Nasdaq Hearings Panel will consider this matter in their decision regarding the company's continued listing on The Nasdaq Capital Market.